LTRN - Lantern Pharma Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
12.87
-0.23 (-1.76%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close13.10
Open13.02
Bid11.00 x 1100
Ask0.00 x 1100
Day's Range12.87 - 13.22
52 Week Range11.51 - 15.44
Volume9,329
Avg. Volume123,642
Market Cap80.02M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 450 Million Data Points, Ahead of Schedule, and Accelerates the Company’s Path to 1 Billion Data Points Curated Specifically for Oncology Drug Development and Drug Response Prediction

    Lantern Pharma (NASDAQ: LTRN), a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from its targeted oncology therapies, announced today that it surpassed the milestone of 450 million curated data points being utilized in its proprietary A.I. and machine learning-powered platform, RADR® (Response Algorithm for Drug Positioning and Rescue). RADR® leverages genomic, transcriptomic, clinical and drug sensitivity data points across more than 145 drug-tumor interactions to predict the potential response cancer patients will have to potential drugs, therefore enabling a more personalized approach to therapy that is aimed at better outcomes.

  • GlobeNewswire

    Lantern Pharma Announces Two Presentations at American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting

    Lantern Pharma (LTRN), a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from its targeted oncology therapies, announced today that it will make two presentations at the upcoming American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting, a meeting of global leaders in cancer research taking place from June 22-24, 2020. Each presentation will examine Lantern Pharma’s use of its A.I. platform, RADR® (Response Algorithm for Drug Positioning and Rescue), in the development of LP-184, one of three cancer drugs in Lantern Pharma’s pipeline.

  • GlobeNewswire

    Lantern Pharma Announces Closing of Initial Public Offering

    Lantern Pharma Inc. (LTRN) (the “Company”), a clinical stage biotechnology company, focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from its targeted oncology therapies, today announced the closing of its initial public offering of 1,750,000 shares of its common stock at a public offering price of $15.00 per share, for gross proceeds of $26,250,000, before deducting underwriting discounts, commissions and offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 262,500 shares of common stock at the initial public offering price, less the underwriting discount, to cover over-allotments.